Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...

The Cleveland Clinic also warns against buying into the “nature’s Ozempic” hype but says the supplement could also aid in ...

While people today are more sensitive to diet culture and unhealthy weight loss methods, there’s also such a stigma ...

Hims & Hers reported its Q4 earnings this week. The company is growing quickly but faces a potential legal threat to its ...

When the FDA declared an Ozempic and Wegovy shortage, business boomed for pharmacies making cheaper, off-brand versions of ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

Jab for joy? A landmark study of nearly 30,000 patients found that the use of GLP-1 medications, which include Wegovy and Ozempic, could have “an antidepressant effect,” suggesting ...

Health insurance companies are lobbying against proposals that would expand prescription access to weight-loss medications.

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

Like so many issues in life, taking a short walk or spin on your bike, can provide some relief when it comes to food noise.